Hinova Pharmaceuticals, Inc.SSE: 688302

Report for Q3 2024

Oct 26, 2024 · Issued by Hinova Pharmaceuticals, Inc. via Shanghai Stock Exchange

Filed with SSE · Oct 26, 2024

On 6ix: 6ix.com/news/report-for-q3-2024-393

Report for Q3 2024

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Hinova Pharmaceuticals, Inc. on 6ix

Earlier from Hinova Pharmaceuticals

Voluntary Disclosure on Obtaining the Notice of Approval for Clinical Trial of Oral PROTAC Drug HP568 Tablets in the Treatment of ER+/HER2- Advanced Breast CancerOct 16, 2024
Announcement on Expiration of the Shareholding Reduction Plan for Shareholders with Over 5% Shares and Equity Change Reaching 1%Oct 15, 2024
Announcement on Voluntary Disclosure of Obtaining FDA Approval for Clinical Trial Application for HP515 Tablets to Treat Metabolic Dysfunction-Associated Steatohepatitis (MASH)Sep 14, 2024
Announcement on Attending Semi-annual Collective Performance Briefing 2024 for Pharmaceutical and Biological Products Companies on STAR MarketSep 7, 2024
Announcement on Voluntary Disclosure of Receiving the Notice of Approval for Clinical Trials of HP515 Tablets for the Treatment of Non-alcoholic Steatohepatitis (NASH)Aug 28, 2024

Later from Hinova Pharmaceuticals

All Hinova Pharmaceuticals news releases

Follow Hinova Pharmaceuticals into a list and get an email when it puts out news.

Follow Hinova Pharmaceuticals